Technology
Health
Pharmaceutical

Tyme Technologies

$1.38
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell TYME and other stocks, options, ETFs, and crypto commission-free!

About

Tyme Technologies, Inc. operates as a clinical-stage biopharmaceutical company focused on development and commercialization of highly targeted cancer therapeutics with a broad range of oncology indications. Its clinical program, SM-88 is a novel combination therapy based on dysfunctional metyrosine derivatives and has shown complete or partial imaging responses in 15 different cancer subtypes, including solid tumors, sarcomas, gliomas and hematological malignancies, without demonstrating drug-related severe adverse events. Read More The company was founded on November 22, 2011 and is headquartered in New York, NY.

Employees
11
Headquarters
New York, New York
Founded
2011
Market Cap
142.40M
Price-Earnings Ratio
Dividend Yield
Average Volume
516.19K
High Today
$1.41
Low Today
$1.30
Open Price
$1.39
Volume
162.09K
52 Week High
$4.64
52 Week Low
$1.30

Collections

Technology
Health
Pharmaceutical
Medical
Therapy
Cancer Prevention
Biopharmaceutical
2015 IPO

News

Yahoo FinanceMay 9

Tyme Technologies to Participate at the Oppenheimer Oncology Insight Summit on May 16th

NEW YORK, May 09, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will participate at the Oppenheimer Oncology Insight Summit in New York on Thursday, May 16, 2019. In one-on-one settings, the company will present its corporate overview for 2019 with special focus on advances in the science of cancer metabolism and clinical developments in lead candidate SM-88 (racemetyrosine) in pancr...

152
NasdaqMay 2

Tyme Technologies To Present at BioNJ's 9th Annual BioPartnering Conference on May 8th, 2019

NEW YORK, May 02, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present a corporate overview for 2019 at the BioNJ 9th Annual BioPartnering Conference on Wednesday, May 8, 2019. Co-sponsored by J.P. Morgan and Johnson & Johnson Innovation, the conference brings together biopharmaceutical companies, investors, and academic collaborators across the Northeast to Mid-Atla...

84
Yahoo FinanceMay 1

Tyme Technologies to Participate at the SunTrust Robinson Humphrey 5th Annual Life Sciences Summit on May 7th

NEW YORK, May 01, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the SunTrust Robinson Humphrey’s 5th Annual Life sciences Summit in New York on May 7th. In one-on-one settings, the company will present its corporate overview for 2019 with special focus on advances in science and clinical developments in oncology and orphan diseases. Event: SunTrust Robinson Humphre...

56

Earnings

Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Available May 29, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.